NCT07154485 - Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions

Dementia Frontotemporal

Interventions

DRUG

NS101 IV infusion

NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases

DRUG

Placebo IV Infusion

Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101